IGC Pharma, Inc. provided details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner. A key pathological marker of Alzheimer's disease is the formation of abnormal clusters of protein fragments called amyloid-beta (Ab) that deposit as Ab plaque between neurons in the brain and contribute to cognitive decline and memory loss. The two drugs approved by the FDA, Aducanumab and Lecanemab, aim to clear Ab plaque from the brain as part of a therapeutic approach focused on modifying the course of the disease.

TGR-63 is a patent pending molecule designed to disrupt the structure of Ab plaque aggregation by disrupting intermolecular interactions and destabilizing their assembly. Studies in Alzheimer's cell line have confirmed TGR-63's potency in alleviating Ab plaque burden. As a result, large clusters of plaque fail to form, potentially st restricting the progression of Alzheimer's Disease.

TGR-63's potential as an Alzheimer's therapeutic was further corroborated in a genetically modified mouse model mimicking Alzheimer's amyloid pathology. In that trial, the group treated with TGR-63, compared to the vehicle-treated group, showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to thwart the progression of Alzheimer's disease. Notably, based on research, the company believe that TGR-63 exhibits excellent biocompatibility and the capacity to penetrate the blood-brain barrier.

IGC Pharma hopes to progress TGR-63 into human trials. The Company is currently advancing IGC-AD1, a CB1 receptor partial agonist, through a Phase 2b trial aimed at alleviating agitation in dementia due to Alzheimer?s Disease. This trial spans twelve sites across the U.S. and Canada, with data milestones based on patient recruitment efficiency anticipated in the second half of 2024.

Successful readout of data from the trial can potentially generate significant value for the Company and, with further confirmations, address a profound unmet need, alleviating caregiver distress, reducing medication dependency, and curbing hospital admissions.